1114 related articles for article (PubMed ID: 29661141)
1. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
[TBL] [Abstract][Full Text] [Related]
2. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
Chiereghin A; Potena L; Borgese L; Gibertoni D; Squarzoni D; Turello G; Petrisli E; Piccirilli G; Gabrielli L; Grigioni F; Lazzarotto T
J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29305542
[TBL] [Abstract][Full Text] [Related]
4. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
[TBL] [Abstract][Full Text] [Related]
5. QuantiFERON-Cytomegalovirus Assay for Prediction of Cytomegalovirus Viremia in Kidney Transplant Recipients: Study From High Cytomegalovirus Seroprevalence Country.
Pongsakornkullachart K; Chayakulkeeree M; Vongwiwatana A; Kantakamalakul W; Skulratanasak P; Phoompoung P
Front Cell Infect Microbiol; 2022; 12():893232. PubMed ID: 35646728
[TBL] [Abstract][Full Text] [Related]
6. Real-world experience of Quantiferon-CMV directed prophylaxis in lung transplant recipients.
Gardiner BJ; Lee SJ; Robertson AN; Cristiano Y; Snell GI; Morrissey CO; Peleg AY; Westall GP
J Heart Lung Transplant; 2022 Sep; 41(9):1258-1267. PubMed ID: 35868965
[TBL] [Abstract][Full Text] [Related]
7. Expanded valganciclovir prophylaxis in kidney transplant recipients is associated with lower incidence of cytomegalovirus infection.
Večerić-Haler Ž; Bizjak B; Romozi K; Arnol M
Clin Nephrol; 2017 Supplement 1; 88(13):126-130. PubMed ID: 28601128
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors of spontaneous CMV DNAemia clearance in kidney transplantation.
Noble J; Gatault P; Sautenet B; Gaudy-Graffin C; Beby-Defaux A; Thierry A; Essig M; Halimi JM; Munteanu E; Alain S; Buchler M
J Clin Virol; 2018; 99-100():38-43. PubMed ID: 29306112
[TBL] [Abstract][Full Text] [Related]
9. CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor.
Schachtner T; Stein M; Reinke P
Transplantation; 2017 Oct; 101(10):e315-e325. PubMed ID: 28594749
[TBL] [Abstract][Full Text] [Related]
10. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
Lautenschlager I; Loginov R; Mäkisalo H; Höckerstedt K
J Clin Virol; 2015 Oct; 71():73-5. PubMed ID: 26318605
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis.
Boudreault AA; Xie H; Rakita RM; Scott JD; Davis CL; Boeckh M; Limaye AP
Transpl Infect Dis; 2011 Jun; 13(3):244-9. PubMed ID: 21414119
[TBL] [Abstract][Full Text] [Related]
12. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
[TBL] [Abstract][Full Text] [Related]
14. Extended Low-Dose Valganciclovir Is Effective Prophylaxis Against Cytomegalovirus in High-Risk Kidney Transplant Recipients With Near-Complete Eradication of Late-Onset Disease.
Fayek SA; Beshears E; Lieber R; Alvey N; Sauer A; Poirier J; Hollinger EF; Olaitan OK; Jensik S; Geyston J; Brokhof MM; Hodowanec AC; Hertl M; Simon DM
Transplant Proc; 2016; 48(6):2056-2064.e1. PubMed ID: 27569944
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of a cytomegalovirus-specific T cell assay in assessing the risk of post-prophylaxis cytomegalovirus infection and post-treatment relapse.
Dioverti MV; Bhaimia E; Yetmar ZA; Melendez DP; Misner L; Beito E; Deziel PJ; Theel ES; Razonable RR
Clin Transplant; 2023 Dec; 37(12):e15143. PubMed ID: 37805968
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients.
Reischig T; Vlas T; Kacer M; Pivovarcikova K; Lysak D; Nemcova J; Drenko P; Machova J; Bouda M; Sedivcova M; Kormunda S
J Am Soc Nephrol; 2023 May; 34(5):920-934. PubMed ID: 36749127
[TBL] [Abstract][Full Text] [Related]
18. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.
McKeen JT; Tsapepas DS; Li H; Anamisis A; Martin ST
Prog Transplant; 2015 Mar; 25(1):39-44. PubMed ID: 25758799
[TBL] [Abstract][Full Text] [Related]
19. Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients Is Associated with Protracted Cold Ischemic Time of Seropositive Donor Organs.
Schlott F; Steubl D; Hoffmann D; Matevossian E; Lutz J; Heemann U; Hösel V; Busch DH; Renders L; Neuenhahn M
PLoS One; 2017; 12(1):e0171035. PubMed ID: 28129395
[TBL] [Abstract][Full Text] [Related]
20. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
